Micronutrient Status and Breast Cancer: A Narrative Review

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(9), P. 4968 - 4968

Published: May 2, 2024

Breast cancer is one of the most common cancers worldwide, at same time being prevalent causes women’s death. Many factors such as alcohol, weight fluctuations, or hormonal replacement therapy can potentially contribute to breast development and progression. Another important factor in onset includes micronutrient status. In this narrative review, we analyzed 23 micronutrients their possible influence on Further, aim study was investigate impact status prevention its various therapeutic pathways. We researched meta-analyses, systemic reviews, retrospective studies, well original studies human animal models. The results these indicate a correlation between different levels decreased risk better survival rate. However, further are necessary establish adequate doses supplementation chosen exact mechanisms therapy.

Language: Английский

---

Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy

Diagnostics, Journal Year: 2023, Volume and Issue: 13(14), P. 2390 - 2390

Published: July 17, 2023

Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive mammary epithelial tumor characterized by lack of expression for estrogen receptors progesterone receptors, absence epidermal growth factor receptor (HER)2 amplification. Corresponding to 15–20% all cancers well-known its poor clinical outcome, this negative deprives TNBC from targeted therapy makes management therapeutically challenging. Type 2 diabetes mellitus (T2DM) common ageing metabolic disorder due insulin deficiency or resistance resulting in hyperglycemia, hyperinsulinemia, hyperlipidemia. Due hormonal imbalances, there are many interplays between both chronic disorders leading increased risk cancer, especially TNBC, diagnosed T2DM patients. The purpose review provide up-to-date information related epidemiology clinicopathological features, factors, diagnosis, biomarkers, current therapy/clinical trials patients with compared non-diabetic counterparts. Thus, in-depth investigation diabetic complications on onset, development, progression discovery biomarkers would improve through early tailoring a better outcome TNBC.

Language: Английский

---

Vitamin D3 Inhibits the Viability of Breast Cancer Cells In Vitro and Ehrlich Ascites Carcinomas in Mice by Promoting Apoptosis and Cell Cycle Arrest and by Impeding Tumor Angiogenesis

Cancers, Journal Year: 2023, Volume and Issue: 15(19), P. 4833 - 4833

Published: Oct. 2, 2023

The incidence of aggressive and resistant breast cancers is growing at alarming rates, indicating a necessity to develop better treatment strategies. Recent epidemiological preclinical studies detected low serum levels vitamin D in cancer patients, suggesting that may be effective mitigating the burden. However, molecular mechanisms D3 (cholecalciferol, vit-D3)-induced cell death are not fully elucidated. vit-D3 efficacy activation was assessed using carcinoma lines vitro widely used Ehrlich ascites (EAC) model vivo Swiss albino mice. Both estrogen receptor-positive (ER+, MCF-7) -negative (ER-, MDA-MB-231, MDA-MB-468) absorbed about 50% over 48 h incubation. retarded proliferation dose-dependent manner with IC50 values ranging from 0.10 0.35 mM. Prolonged (up 72 h) did enhance anti-proliferative efficacy. Vit-D3-induced growth arrest mediated by upregulation p53 downregulation cyclin-D1 Bcl2 expression levels. Vit-D3 migration inhibited blood vessel as well chorioallantoic membrane (CAM) assay. intraperitoneal administration solid tumor reduced body weight gain, mice liquid model. In summary, cytotoxic effects an EAC were associated inhibition, induction apoptosis, cycle arrest, impediment angiogenic processes. generated data warrant further on anti-cancer therapeutic applications.

Language: Английский

---

A Plea for Monitoring Serum Selenium Levels in Breast Cancer Patients: Selenium Deficiency Is Rare during the First Year of Therapy, and Selenium Supplementation Is Associated with Elevated Risk of Overdosing

Nutrients, Journal Year: 2024, Volume and Issue: 16(13), P. 2134 - 2134

Published: July 4, 2024

(1) Background: The role of selenium in cancer biology remains poorly understood. Our aim was to study the course serum levels and use supplements during breast therapy. (2) Methods: Serum levels, clinical–pathological data, supplementation, lifestyle factors were monitored quarterly over one year. (3) Results: A total 110 non-metastatic patients enrolled prospective observational “BEGYN-1” study. At baseline, 2.9% selenium-deficient (<50 ng/mL), 1.9% overdosed (>120 6.4% received substitution. median level 81.5 ng/mL ranged between 78.7 84.5 within 25.3% resulting significantly higher (p < 0.05). 8.7–28.6% using overdosed. Selenium strongly correlated with mushroom consumption = 0.003), but no association found therapy or clinical characteristics. (4) Conclusions: Although deficiency is rare, should be assessed patients. Mushrooms nuts preferred correct deficiency. Ruling out helps prevent risk selenosis avoid unnecessary, costly supplementation who are often financially burdened due their disease.

Language: Английский

---

Dynamics of T cell subpopulations and plasma cytokines during the first year of antineoplastic therapy in patients with breast cancer: the BEGYN-1 study

Breast Cancer Research, Journal Year: 2025, Volume and Issue: 27(1)

Published: April 1, 2025

Abstract Background The role of T cell immunity during antineoplastic therapy is poorly understood. In the BEGYN-1 study, patients with breast cancer underwent quarterly assessments prior to and over a period 12 months. Methods We used flow cytometry multiplex immunoassays quantify 25 subpopulations seven associated plasma cytokines in peripheral blood from 92 non-metastatic patients, respectively. addition, association between dynamics outcome undergoing neoadjuvant chemotherapy was investigated. Results chemotherapy, significant reduction helper (Th) cells, particularly naïve central effector cells thymus positive Th observed time. Interestingly, Th1 immune response-associated (IL-12, TNF, IFN-γ) declined while Th2 cytotoxic increased Conclusions conclude that transition response towards an increase whereas without these alterations were less pronounced. Future studies should clarify whether patterns subsets or can be as biomarkers monitor even improve therapeutic interventions. Graphical abstract

Language: Английский

---

Pretreatment plasma vitamin D and response to neoadjuvant chemotherapy in breast cancer: evidence from pooled analysis of cohort studies

International Journal of Surgery, Journal Year: 2024, Volume and Issue: 110(12), P. 8126 - 8135

Published: Nov. 18, 2024

Background: Biological evidence has revealed antitumor effect of vitamin D, but whether it could predict the response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients remains inconclusive. The aim was investigate association between pretreatment D level and NAC subsequent survival outcomes BC patients. Materials methods: authors systematically searched Medline, Embase, Cochrane Library, Web Science databases clinical trial registries identify relevant articles from inception 8 October 2024. Eligible studies investigating associations plasma were selected according predefined criteria, with study characteristics extracted by two reviewers. primary outcome pathological complete (pCR), while overall event-free (EFS) adopted as secondary outcomes. Summary estimates odds ratios (ORs) or hazard (HRs) 95% CIs pooled using a random-effects model. Subgroup sensitivity analyses performed based on methodological quality. Results: Six retrospective cohort involving 1291 included. observed significant deficiency 50% increased non-pCR after (OR=1.50, CI: 1.11–2.03, P =0.008) no heterogeneity ( I 2 =0%). also identified (OR=1.33, 1.01–1.75, =0.046). A similar EFS (HR=1.27, 0.92–1.75, =0.139) noted although estimate not statistically significant. Sensitivity quality showed consistent findings. Conclusion: Pretreatment is associated an inferior Our meta-analysis advocates further prospective large sample sizes before supplementation be administered improve prognosis

Language: Английский

---

Course of Vitamin D Levels in Newly Diagnosed Non-Metastatic Breast Cancer Patients over One Year with Quarterly Controls and Substitution

Nutrients, Journal Year: 2024, Volume and Issue: 16(6), P. 854 - 854

Published: March 15, 2024

(1) Background: Vitamin D levels in patients remain inadequately understood, with research yielding inconsistent findings. Breast cancer patients, particularly due to oncological therapies, face an increased risk of osteopenia, which can be exacerbated by a vitamin deficiency. (2) Methods: The prospective observational “BEGYN-1” study assessed serum 25(OH)D at baseline and quarterly thereafter. Clinical, pathological, nutritional, supplementation, lifestyle data were recorded. (3) Results: Before treatment, 68.5% deficient (<30 ng/mL), 4.6% experiencing severe deficiency (<10 ng/mL). median 24 ng/mL (range: 4.8 64.7 Throughout the study, 48 22.0 76.7 diagnosis, 16.7% received substitution, 97.8% substitution throughout year weekly dose 20,000 IU. It took least three assessments for 95% reach normal range. A multiple GEE analysis identified associations between season, age, VLDL, magnesium levels, endocrine therapy. (4) Conclusions: Physicians should monitor before, during, after therapy prevent adjust individually. While variables such as seasons, magnesium, diet, interventions affect supplementation has greatest impact.

Language: Английский

---

Improved awareness of physical activities is associated with a gain of fitness and a stable body weight in breast cancer patients during the first year of antineoplastic therapy: the BEGYN-1 study

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Aug. 11, 2023

Breast cancer is the most frequent in women. Reduced physical activity and overweight are associated with poor prognosis. patients have a high risk to gain weight, lose muscle mass reduce during therapy. Concepts urgently needed motivate engage activity.110 non-metastatic breast were included prospective observational BEGYN-1 study. Physiological parameters body composition measured before start of therapy then quarterly for one year. Patients used fitness tracker documented their diary throughout study.Although not offered any guided exercise, despite restrictions COVID-19 pandemic, they increased (metabolic equivalent task (MET) -minutes): p<0.001), (decreasing resting heart rate: p=0.001) did weight (median - 0.4kg) over course study.Improved awareness an increase activity, fitness, stable first year patients. Counselling at diagnosis should wear document activities.

Language: Английский

---

Effects of Selective and Nonselective Beta Blockers on Bone Mineral Density in Mexican Patients with Breast Cancer

Cancers, Journal Year: 2024, Volume and Issue: 16(16), P. 2891 - 2891

Published: Aug. 20, 2024

Breast cancer (BCa) is related to chronic stress and can reduce the bone mineral density (BMD) through neurochemicals beta-adrenergic receptor (ADRB) 1 2. Selective beta blockers (sBBs) nonselective (nsBBs) are used treat systemic arterial hypertension (SAH) may have osteoprotective effects, as they inhibit ADRBs. To evaluate effects of sBBs nsBBs on BMD Mexican patients with BCa. A retrospective study was conducted. We included 191 women BCa without SAH treated nsBBs, sBBs, diuretics. evaluated using a scan (DEX scan). greater average (p < 0.05) observed in prior treatment both (0.54 ± 0.94 −0.44 1.22, respectively) compared diuretics or (−1.73 0.83 −1.22 0.98, respectively). Regarding diagnosis osteoporosis/osteopenia, no cases were whereas 5.6% presented osteopenia. total 23.1% 10.6% managed osteoporosis 61.5% 48% loop osteopenia, respectively 0.05). Treatment promising option for prevention management osteoporosis/osteopenia BCa; however, further prospective studies needed.

Language: Английский

---

The status of serum 25(OH)D levels is related to breast cancer

Cancer Treatment and Research Communications, Journal Year: 2024, Volume and Issue: 42, P. 100870 - 100870

Published: Jan. 1, 2024

Breast cancer is the second most common among women and leading cause of cancer-related mortality in this population. Numerous factors have been identified as either risk or protective for breast cancer. However, role Vitamin D (Vit. D) remains contentious, with conflicting findings literature. The present study aimed to compare serum Vit. levels between without This cross-sectional included 40 diagnosed cancer, referred Mahdia Hamadan Radiotherapy Center 2022. These participants were matched age- level-matched Serum measured using ELISA method. Statistical analysis was performed SPSS version 26, a significance threshold set at 95% confidence level. mean ± standard deviation 31.9 28.27 ng/mL 37.98 15.89 ng/mL, respectively (P = 0.024). prevalence insufficiency 50% group 27.5% control group, while 72.5% had sufficient 0.008). In lower significantly associated educational < 0.001), economic social status 0.001). A weak positive correlation observed patient age (r 0.162, P 0.152). significant difference suggests that deficiency may be risk. support hypothesis improving could potentially reduce incidence

Language: Английский

---